Galectin Therapeutics CMO Exercises Options and Sells Shares Under 10b5-1 Plan

Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc, exercised stock options and sold shares on June 23, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026. Khurram exercised options to acquire 7,557 shares of common stock at $1.23 per share and immediately sold the same number of shares at a weighted average price of $3.14 per share, resulting in no net change in his direct holdings. The options were part of a vesting schedule with quarterly installments. The sale was executed in multiple transactions at prices ranging from $3.10 to $3.17 per share. Following the transactions, Khurram retains 32,500 stock options. This Form 4 filing documents the insider transactions as required by SEC regulations.